In one niche, the risk to women is too great
By Judy Norsigian,
The Boston Globe
| 11. 14. 2010
[Op-Ed]
Not all stem cell research is in women's best interest.
The issue of embryonic stem cell research has long been clouded by certain activists — notably those from conservative Christian groups — who seek to stop all such research because it involves destruction of an embryo. In contrast, many pro-choice women’s health advocates like my own organization have long supported most embryonic stem cell research. But there is a small subset of this research we oppose — somatic cell nuclear transfer (SCNT, also called embryo cloning or research cloning) — because of substantial concerns about health risks for the women who provide the fresh eggs that this research demands.
As part of SCNT, the nucleus of an egg (from an egg donor) is removed, and the nucleus of an adult stem cell is inserted in its place. By contrast, conventional embryonic stem cell research utilizes otherwise discarded embryos from fertility clinics, and does not require freshly harvested eggs, where women undergo the risks of egg extraction solely for research purposes. This distinction is crucial.
Because thousands of women regularly undergo...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...